诺和龙与其联合应用二甲双胍对初发2型糖尿病患者血糖控制的作用

Efficacy and safety of Novolon (Repaglinide) with and without metformin in treatment of type 2 diabetes mellitus

关键词:  瑞格列奈  二甲双胍  2型糖尿病

Key words:  repeglinide  metformin  type 2 diabetes mellitus

摘要:

［目的］ 评价单用诺和龙（瑞格列奈）与其联合二甲双胍治疗初发2型糖尿病的有效性和安全性。［方法］选择初发2型糖尿病(T2DM)患者50例，分为单用诺和龙组（单用组）和二甲双胍联合应用组（联合组），治疗3个月，评估疗效及副作用的发生情况。［结果］单用诺和龙组和联合应用二甲双胍组治疗后的空腹血糖、餐后2 h血糖及糖化血红蛋白均比用药前明显降低（P<0.001），但体重与治疗前无显著性差异（P>0.05）。取联合组患者餐后2 h血糖（8.55±2.13）mmol/L明显低于单用组 （9.19±1.55）mmol/L（P<0.05），但空腹血糖及糖化血红蛋白变化二组间差别无显著性意义（P>0.05）。安全性分析表明，患者对诺和龙有较好的耐受性，尤其是低血糖的发生率明显降低。［结论］诺和龙可作为治疗2型糖尿病的有效降糖药，与二甲双胍合用时可明显控制餐后高血糖，同时可改善T2DM患者对治疗的顺应性。

Abstract:

［Objective］To compare the therapeutic efficacy of administration of Novolon (repaglinide) with and without metformin in the patients with Type 2 diabetes mellitus (T2DM) primarily diagnosed.［Methods］The patients with 50 T2DM were randomly divided into repaglinide group and repaglinide+metformin group respectively for 3-month-treatment.［Results］Fasting plasma glucose (FPG)，2 hours postprandial plasma glucose (2hPG)，HbA1c were decreased significantly in both of the groups after three months of treatment (P<0.001)，but weight (W) (P>0.05). The 2hPG in repaglinide+metformin (8.55±2.13)mmol/L was lower than that in repaglinide (9.19±1.55)mmol/L(P<0.05). No hypoglycemia was observed.［Conclusions］The repaglinide is effective and safe in treating T2DM primarily diagnosed. The repaglinide with metformin is better use in controling 2 h PG.